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Abstract Recombinant human erythropoietin (rhEPO)
treatment of hemodialyzed (HD) patients normalizes the
altered phenotype of CD4+ lymphocytes and restores the
balance of Th1/Th2 cytokines. We decided to test how the
presence of rhEPO in cell culture modulates cytokine pro-
duction of CD4+ lymphocytes in HD patients with stable
hemoglobin level and expression of activation antigens of
stimulated CD4+ lymphocytes similar to those observed in
healthy individuals. We also tested whether the presence of
rhEPO in cell culture protects stimulated CD4+ lymphocytes
of HD patients from apoptosis. Peripheral blood mononu-
clear cells (PBMC) of HD patients were stimulated with an
immobilized anti-CD3 antibody with or without addition of
rhEPO. The percentage of apoptotic CD4+ lymphocytes and
the level of Th1/Th2 cytokines in culture supernatants were
measured with flow cytometry. HD patients showed a de-
crease in the percentage of apoptotic CD4+ cells after stim-
ulation with the anti-CD3 antibody combined with rhEPO.
The level of IFN-g and IL-10 was increased while the level
of TNF-α was decreased in the presence of rhEPO in cell
culture from HD patients. These results confirm the role of
rhEPO signaling in T lymphocytes of HD patients.
Keywords CD4+ lymphocytes . apoptosis . cytokines .
rhEPO
Introduction
Chronic renal failure is accompanied by a deficiency state in
both cell-mediated and humoral immunity which is deepened
by hemodialysis (HD) [1]. A direct contact of the patient’s
peripheral blood mononuclear cells (PBMC) with an artificial
membrane increases the production of pro-inflammatory cyto-
kines: tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1
and IL-6 [2, 3]. What’s more, HD patients demonstrate a
decreased production of IL-2 and interferon gamma (IFN-g)
[4, 5]. The deficient production of cytokines is probably
related to changes in phenotype of CD4+ lymphocytes from
HD patients, which exhibit decreased expression of the major
co-stimulatory CD28 antigen and main activation markers:
CD25 and CD69 [6].
Recombinant human erythropoietin (rhEPO) adminis-
tered to HD patients to correct the anemia state can influ-
ence both the phenotype of T lymphocytes and the
production of cytokines. Our previous studies have shown
that rhEPO treatment normalizes the impaired expression of
CD28 and CD69 antigens of CD4+ lymphocytes [7]. Addi-
tionally, several months of therapy restores the balance of
cytokines by reducing the level of TNF-α [8, 9] and increas-
ing the level of IL-2 and IL-10 [4, 8, 9] in whole blood cell
cultures of HD patients during treatment. However, the
levels of cytokines change in a different ways during rhEPO
treatment. The level of TNF-α and IL-10 changes immedi-
ately when the hemoglobin level exceeds the optimal value
of 10 g/dl and is stable during treatment, while the level of
IL-2 increases continuously during treatment [9]. This
observation suggests that the normalization of the levels of
TNF-α and IL10 was reached shortly after the start of
rhEPO therapy. Increase of the level of IL-2 has been
achieved after several months of rhEPO administration, so
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this change was secondary with respect to changes in the
level of TNF-α and IL10. Probably changes in the level of
these cytokines are dependent upon various factors. For
example, the level of IL-2 may depend on increased expres-
sion of CD28 on CD4+ lymphocytes and/or decreased
percentage of CD152+ lymphocytes. However, it is still
not clear which cytokines are regulated by the presence of
erythropoietin in the circulation.
In order to better understand these mechanisms, we decided
to test how the presence of rhEPO in cell culture influences
cytokine production in stimulated CD4+ lymphocytes from
HD patients with a stable hemoglobin level and expression of
CD28, CD69 and CD25 antigens of stimulated CD4+
lymphocytes similar to those observed in healthy individ-
uals. Repetitive HD procedure has also been reported to
induce apoptosis of T lymphocytes, which leads to T-cell
lymphopenia sometimes observed in these patients [10].
Therefore, we also tested if the presence of rhEPO in cell
culture can protect stimulated CD4+ lymphocytes of HD
patients from apoptosis.
Patients and Methods
Patients For this study we have chosen 13 HD patients
(11 men and 2 women, mean age 59±13.99 years) with
a hemoglobin level above 10 g/dl (mean hemoglobin
12.53±1.57 g/dl) and expression of CD28, CD69 and
CD25 antigens of stimulated CD4+ lymphocytes similar to
those observed in healthy controls. 7 HD patients received
epoetin alpha or beta and the epoetin doses were adjusted to
hemoglobin levels. 6 HD patients who didn’t receive rhEPO
were also included in the study group. These patients did not
require rhEPO administration, since the level of hemoglobin
was maintained at the correct level. They showed similar
phenotype of stimulated CD4+ lymphocytes and the level of
Th1 and Th2 cytokines in culture supernatants as HD
patients treated with rhEPO and healthy controls (data not
shown). None of the patients suffered from any infection,
inflammation, malnutrition, malignancy or blood loss dur-
ing the study. The study has been approved by the Ethical
Committee of the Medical University of Gdańsk.
Assessment of the Percentage of Apoptotic CD4+ lymphocytes
and the Level of Th1/Th2 cytokines Thirty milliliters of ve-
nous peripheral blood from each HD patient was collected
in tubes containing EDTA as the anti-coagulant agent before
HD session. Peripheral blood mononuclear cells (PBMC)
were isolated from venous peripheral blood as previously
described [6] and stimulated with an immobilized anti-CD3
antibody (125 ng/ml) with or without the addition of rhEPO
(epoetin alpha, 0.1 U/ml) and incubated for 3 days at 37 °C,
5 % CO2. Stimulated cells were then collected in order to
estimate the percentage of apoptotic CD4+ lymphocytes.
Culture supernatants were collected and frozen at −80 °C
for the assessment of cytokine production. Collected cells
were stained with the RPE-Cy5-conjugated anti-CD4 mono-
clonal antibody (DAKO, Denmark) and PE-conjugated
annexin V (BD Pharmingen, USA) and analyzed with flow
cytometry on FACScan (Becton Dickinson, USA).
Cytometric Bead Array (CBA™, BD Biosciences, USA)
was used to estimate the level of Th1/Th2 cytokines pro-
duced by stimulated PBMC. Cytokine concentrations were
analyzed with the use of Becton Dickinson CBA software.
Fig. 1 Comparison of the percentage of CD4+ cell apoptosis depend-
ing on the presence of rhEPO in cell culture. Lymphocytes were
selected on the basis of their forward and side scatter characteristics.
Annexin V binding assay was used to distinguish between viable
and apoptotic cells—apoptotic CD4+ lymphocytes were annexin V
positive (CD4+Annexin V+ cells). Graph shows the percentage of
CD4+Annexin V+ cells in HD patients. Midpoints of figures
present medians, boxes present the 25 and 75 percentile and
whiskers outside visualize the minimum and maximum of all the
data, p<0.05, Wilcoxon signed ranks test
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Analysis and Statistics Data were analyzed with Cyflogic,
version 1.2.1 (©Perttu Terho and ©CyFlow Ltd). Statistical
analysis was done using the Statistica program, version
8 (StatSoft, Poland). The significance tests were chosen
according to data distribution. The level of significance in
all was p≤0.05.
Results and Discussion
The expression of erythropoietin receptor (EPO-R) has been
reported in many non-hematopoietic cells including lympho-
cytes [11]. We have recently shown that rhEPO increases the
phosphorylation of signal transducer and activator of transcrip-
tion 5 (STAT5) in stimulated CD4+ lymphocytes [12]. Phos-
phorylation of STAT5 in T lymphocytes plays an important role
in promoting their survival. Meanwhile, repetitive HD proce-
dure has been reported to induce apoptosis of T lymphocytes
[10]. Therefore, we examined whether the presence of rhEPO
in cell culture can protect stimulated CD4+ lymphocytes of HD
patients from apoptosis and we have shown that if present at a
concentration similar to the physiological level rhEPO pro-
motes the survival of CD4+ lymphocytes. HD patients showed
a significant decrease in the percentage of apoptotic CD4+ cells
(CD4+Annexin V+ cells) after stimulation with the anti-CD3
antibody combinedwith rhEPO as compared to cells stimulated
with the anti-CD3 antibody alone (Fig. 1). This fact has been
observed in other cell types and our team is being the first to
described it in T lymphocytes.
We also investigated the level of Th1 cytokines (IL-2,
IFN-g, TNF-α) and Th2 cytokines (IL-4, IL-5, IL-10) in
culture supernatants of lymphocytes stimulated with the
anti-CD3 antibody with or without addition of rhEPO. We
didn’t observe any changes in the level of IL-2 in culture
supernatants of lymphocytes stimulated with the anti-CD3
antibody in the presence of rhEPO. Since the phenotype of
Fig. 2 Comparison of the
levels of Th1 and Th2 cytokines
in culture supernatants of
stimulated lymphocytes
depending on the presence of
rhEPO. Graphs show the level
of Th1 (IL-2, IFN-γ, TNF-α)
and Th2 (IL-4, IL-5, IL-10)
cytokines in HD patients.
Midpoints of figures present
medians, boxes present the 25
and 75 percentile and whiskers
outside visualize the minimum
and maximum of all the data,
p<0.05, Wilcoxon signed
ranks test
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stimulated CD4+ lymphocytes from these patients and the
level of IL-2 in culture supernatants is similar to those
observed in healthy individuals, we suspect that the produc-
tion of IL-2 is dependent on the level of CD28 antigen on
CD4+ lymphocytes, as confirmed by a positive correlation
between these parameters (data not shown). This relation-
ship has already been described by other authors [13].
In our study the presence of rhEPO in cell culture in-
creased the levels of IFN-g and IL-10 (Fig. 2), whose
production can also be enhanced by IL-2 [14, 15]. Since
IL-2 and EPO act through receptors that belong to the same
family and have common signaling pathways [16], we be-
lieve that rhEPO acts like IL-2. The level of TNF-α was
decreased in the presence of rhEPO in cell culture from HD
patients (Fig. 2). It is not clear whether down-regulation of
TNF-α was caused by rhEPO or rather IL-10, whose level
was increased in the presence of rhEPO. The level of IL-4
and IL-5 remained unchanged (Fig. 2). Not the first time we
demonstrate the impact of rhEPO on cytokine levels in HD
patients. Our study shows that rhEPO affects the production
of cytokines which are found to be regulated through sig-
naling pathways involving STAT5, for example. The pres-
ence of rhEPO appears to regulate levels of TNFTNF-α and
IL-10, depending on the initial level of cytokines. Similar
experiment was carried out in a group of healthy people.
Healthy controls had a lower percentage of apoptotic CD4+
cells after stimulation with the anti-CD3 antibody compared
to HD patients so the presence of rhEPO in cell culture
didn’t influence it. Healthy controls also didn’t show any
changes in Th1 or Th2 cytokine levels when rhEPO was
added to cell culture but at the same time the level of TNF-α
was already decreased while the level of IL-10 and IFN-g
was increased compared to HD patients (data not shown).
Conclusions
These results confirm one more time the role of rhEPO sig-
naling in T lymphocytes of HD patients. In our opinion,
rhEPO protects CD4+ lymphocytes from apoptosis and
restores the balance of cytokines by reducing the level of
TNF-α and increasing the level of anti-inflammatory IL-10,
though the mechanism of action of rhEPO on T lymphocytes
is still unclear. At the same time these results suggest that
improved production of IL-2 is not directly dependent on
rhEPO presence but seems to be a consequence of a long-
term rhEPO treatment. These observations confirm that rhEPO
administration not only has a beneficial effect on the red blood
cells but also regulates the functioning of immune cells.
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